Related Experiment Video

Updated: Dec 27, 2025

Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates
05:53

Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates

Published on: July 6, 2013

15.4K

Current Understanding of Cytomegalovirus Reactivation in Critical Illness

Hannah Imlay1, Ajit P Limaye1

  • 1Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA.

The Journal of Infectious Diseases
|March 6, 2020
PubMed

Insights

Cytomegalovirus (CMV) reactivation in critically ill patients is linked to poorer outcomes. Further research, including randomized trials, is needed to confirm if preventing CMV reactivation improves patient survival and to understand the mechanisms involved.

Area of Science:

  • Critical care medicine
  • Infectious diseases
  • Virology

Background:

  • Cytomegalovirus (CMV) reactivation is observed in critically ill adults.
  • Observational studies suggest a link between CMV reactivation and adverse clinical outcomes in intensive care unit (ICU) patients.

Purpose of the Study:

  • To review clinical data on CMV reactivation and outcomes in critically ill patients.
  • To discuss potential biological mechanisms for CMV's impact.
  • To summarize initial interventional trials on CMV prevention.

Main Methods:

  • Review of observational clinical data.
  • Discussion of proposed biological mechanisms.
  • Summary of preliminary interventional trial results.

Main Results:

  • Observational data indicate a correlation between CMV reactivation and worse outcomes in ICU settings.
  • Potential biological mechanisms for CMV's detrimental effects are discussed.
  • Initial interventional trials provide preliminary insights into CMV prevention.

Conclusions:

  • A definitive randomized, placebo-controlled trial is necessary to establish causality.
  • Such a trial will determine if CMV reactivation prevention improves outcomes in critical illness.
  • Further investigation is required to elucidate the underlying mechanisms of CMV's impact.
Keywords:
Cytomegalovirusacute respiratory distress syndromecritical illnesssepsis

More Related Videos

qPCR Is a Sensitive and Rapid Method for Detection of Cytomegaloviral DNA in Formalin-fixed, Paraffin-embedded Biopsy Tissue08:08

qPCR Is a Sensitive and Rapid Method for Detection of Cytomegaloviral DNA in Formalin-fixed, Paraffin-embedded Biopsy Tissue

Published on: July 9, 2014

16.2K
Intracerebroventricular and Intravascular Injection of Viral Particles and Fluorescent Microbeads into the Neonatal Brain05:51

Intracerebroventricular and Intravascular Injection of Viral Particles and Fluorescent Microbeads into the Neonatal Brain

Published on: July 24, 2016

20.3K

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
123
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
714
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
2.4K
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
928
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
671
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
719